Tessa enjoyed big backers, great science and world-class ambition. So what did we learn from its collapse?
Tessa Therapeutics’ website has gone dark. Anyone Googling up references to a review of the pipeline, the people, its hundreds of millions raised for cancer R&D, its still rather new CEO, are led to a simple notice:
“Website is under maintenance.”
But not really.
As Kyle LaHucik ably reported a few days ago, Singapore-based Tessa has folded its tent. And the principals, as usual in a shutdown, don’t have a lot to say about it.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.
